Stem Cell Clinic

BMC Veterinary Research | All articles

By Stell Cell Research

All

Investigating the prevalence of Salmonella in dogs within the Midlands region of the United Kingdom

Preena Lowden, Corrin Wallis, Nancy Gee, Anthony Hilton BMC Veterinary Research 2015, 11:239 (17 September 2015)

Abstract | Full text | PDF | PubMed

Evaluation of inhibition of F4ac positive Escherichia coli attachment with xanthine dehydrogenase, butyrophilin, lactadherin and fatty acid binding protein

Predrag Novakovic, Chandrashekhar Charavaryamath, Igor Moshynskyy, Betty Lockerbie, Radhey Kaushik, Matthew Loewen, Beverly Kidney, Chris Stuart, Elemir Simko BMC Veterinary Research 2015, 11:238 (15 September 2015)

Abstract | Full text | PDF | ePUB | PubMed

Saliva as an alternative specimen for detection of Schmallenberg virus-specific antibodies in bovines

Justas Lazutka, Aliona Spakova, Vilimas Sereika, Raimundas Lelesius, Kestutis Sasnauskas, Rasa Petraityte-Burneikiene BMC Veterinary Research 2015, 11:237 (15 September 2015)

Abstract | Full text | PDF | PubMed

Veterinary homeopathy: Systematic review of medical conditions studied by randomised trials controlled by other than placebo

Robert T Mathie, Jrgen Clausen BMC Veterinary Research 2015, 11:236 (15 September 2015)

Abstract | Full text | PDF | PubMed

Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors

Michle Spoerri, Franco Guscetti, Sonja Hartnack, Alois Boos, Christine Oei, Orsolya Balogh, Renata M Nowaczyk, Erika Michel, Iris M Reichler, Mariusz P Kowalewski BMC Veterinary Research 2015, 11:235 (15 September 2015)

Abstract | Full text | PDF | PubMed

S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs

Mohsen Hanifeh, Romy Heilmann, Satu Sankari, Minna Rajamki, Laura Mkitalo, Pernilla Syrj, Susanne Kilpinen, Jan Suchodolski, Jrg Steiner, Thomas Spillmann BMC Veterinary Research 2015, 11:234 (14 September 2015)

Abstract | Full text | PDF | PubMed

Validity and practical utility of accelerometry for the measurement of in-hand physical activity in horses

R. Morrison, D. Sutton, C. Ramsoy, N. Hunter-Blair, J. Carnwath, E. Horsfield, P. Yam BMC Veterinary Research 2015, 11:233 (11 September 2015)

Abstract | Full text | PDF | PubMed

Induction of ROS generation and NF-B activation in MARC-145 cells by a novel porcine reproductive and respiratory syndrome virus in Southwest of China isolate

Yulin Yan, Aiguo Xin, Qian Liu, Hui Huang, Zhiyong Shao, Yating Zang, Ling Chen, Yongke Sun, Hong Gao BMC Veterinary Research 2015, 11:232 (10 September 2015)

Abstract | Full text | PDF | PubMed

Evaluation of eating and rumination behaviour in 300 cows of three different breeds using a noseband pressure sensor

Ueli Braun, Susanne Zrcher, Michael Hssig BMC Veterinary Research 2015, 11:231 (4 September 2015)

Abstract | Full text | PDF | PubMed

Peroxisome proliferator activated receptor protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation

Chamisa Herrera, Dae Kim, Senthil Kumar, Jeffrey Bryan BMC Veterinary Research 2015, 11:230 (4 September 2015)

Abstract | Full text | PDF | PubMed

Post mortem computed tomography and core needle biopsy in comparison to autopsy in eleven bernese mountain dogs with histiocytic sarcoma

Franziska Hostettler, Dominique Wiener, Monika Welle, Horst Posthaus, Urs Geissbhler BMC Veterinary Research 2015, 11:229 (2 September 2015)

Abstract | Full text | PDF | PubMed

Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up

Chris Rundfeldt, Andrea Tipold, Wolfgang Lscher BMC Veterinary Research 2015, 11:228 (2 September 2015)

Abstract | Full text | PDF | PubMed

Ultrasonographic examination of the spinal cord and collection of cerebrospinal fluid from the atlanto-occipital space in cattle

Ueli Braun, Jeannette Attiger, Carina Brammertz BMC Veterinary Research 2015, 11:227 (2 September 2015)

Abstract | Full text | PDF | PubMed

Screening anthelmintic resistance to triclabendazole in Fasciola hepatica isolated from sheep by means of an egg hatch assay

David Robles-Prez, Jos Martnez-Prez, Francisco Rojo-Vzquez, Mara Martnez-Valladares BMC Veterinary Research 2015, 11:226 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets

Thierry Olivry, Ralf Mueller, Pascal Prlaud BMC Veterinary Research 2015, 11:225 (28 August 2015)

Abstract | Full text | PDF | PubMed

International veterinary epilepsy task force recommendations for systematic sampling and processing of brains from epileptic dogs and cats

Kaspar Matiasek, Mart Pumarola i Batlle, Marco Rosati, Francisco Fernndez-Flores, Andrea Fischer, Eva Wagner, Mette Berendt, Sofie Bhatti, Luisa De Risio, Robyn Farquhar, Sam Long, Karen Muana, Edward Patterson, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:216 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force recommendations for a veterinary epilepsy-specific MRI protocol

Clare Rusbridge, Sam Long, Jelena Jovanovik, Marjorie Milne, Mette Berendt, Sofie Bhatti, Luisa De Risio, Robyn Farqhuar, Andrea Fischer, Kaspar Matiasek, Karen Muana, Edward Patterson, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:194 (28 August 2015)

Abstract | Full text | PDF | PubMed

International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals

Mette Berendt, Robyn Farquhar, Paul Mandigers, Akos Pakozdy, Sofie Bhatti, Luisa De Risio, Andrea Fischer, Sam Long, Kaspar Matiasek, Karen Muana, Edward Patterson, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Mart Pumarola, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:182 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy

Heidrun Potschka, Andrea Fischer, Wolfgang Lscher, Ned Patterson, Sofie Bhatti, Mette Berendt, Luisa De Risio, Robyn Farquhar, Sam Long, Paul Mandigers, Kaspar Matiasek, Karen Muana, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger A Volk BMC Veterinary Research 2015, 11:177 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe

Sofie Bhatti, Luisa De Risio, Karen Muana, Jacques Penderis, Veronika Stein, Andrea Tipold, Mette Berendt, Robyn Farquhar, Andrea Fischer, Sam Long, Wolfgang Lscher, Paul Mandigers, Kaspar Matiasek, Akos Pakozdy, Edward Patterson, Simon Platt, Michael Podell, Heidrun Potschka, Clare Rusbridge, Holger Volk BMC Veterinary Research 2015, 11:176 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Forces current understanding of idiopathic epilepsy of genetic or suspected genetic origin in purebred dogs

Velia-Isabel Hlsmeyer, Andrea Fischer, Paul Mandigers, Luisa DeRisio, Mette Berendt, Clare Rusbridge, Sofie Bhatti, Akos Pakozdy, Edward Patterson, Simon Platt, Rowena Packer, Holger Volk BMC Veterinary Research 2015, 11:175 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force consensus reports on epilepsy definition, classification and terminology, affected dog breeds, diagnosis, treatment, outcome measures of therapeutic trials, neuroimaging and neuropathology in companion animals

Holger Volk BMC Veterinary Research 2015, 11:174 (28 August 2015)

Full text | PDF | ePUB | PubMed

International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs

Luisa De Risio, Sofie Bhatti, Karen Muana, Jacques Penderis, Veronika Stein, Andrea Tipold, Mette Berendt, Robyn Farqhuar, Andrea Fischer, Sam Long, Paul Mandigers, Kaspar Matiasek, Rowena Packer, Akos Pakozdy, Ned Patterson, Simon Platt, Michael Podell, Heidrun Potschka, Mart Batlle, Clare Rusbridge, Holger Volk BMC Veterinary Research 2015, 11:148 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

BoHV-4 immediate early 1 gene is a dispensable gene and its product is not a bone marrow stromal cell antigen 2 counteracting factor

Valentina Franceschi, Antonio Capocefalo, Sarah Jacca, Alfonso Rosamilia, Sandro Cavirani, Fengwen Xu, Wentao Qiao, Gaetano Donofrio BMC Veterinary Research 2015, 11:224 (27 August 2015)

Abstract | Full text | PDF | PubMed

Update on epidemiology of canine babesiosis in Southern France

Magalie Ren-Martellet, Claire Moro, Jeanne Chne, Gilles Bourdoiseau, Luc Chabanne, Patrick Mavingui BMC Veterinary Research 2015, 11:223 (25 August 2015)

Abstract | Full text | PDF | PubMed

More:
BMC Veterinary Research | All articles

Has the FDA given up on regulating stem cell clinics …

By Stem Cell Clinic

What the heck happened to the FDA when it comes to regulating stem cell clinics?

Has it given up?

Or does it just seem that way because it moves in slow motion?

The FDA might as well have thrown in the towelbecause, as I like to say, the stem cell field moves in dog years. Often times 7 years worth of stem cell happenings take place in just onehuman calendar year. An example of this warp speed is the approximate doubling of the number of stem cell clinics in the US in the last year or so.

There was a time when I was perhaps naive enough thatI thought that regulatory agencies legally tasked with oversight of biologics would take swift action against violators, particularly if the products or procedures in question were not proven to be safe or effective. Patients are at serious risk.

Throw in some evidence of predatory behavior and dubious public claims and lack of training at some clinics, and the FDA in the US, for example, surely would do something about it as thousands of patients get these dubious interventions. Right?

Im no so sure anymore.

I still believe in appropriate regulation of stem cell-based medical products and interventions.The FDA has now won their recent legal case on regulating proliferated stem cell products as biological drugs and it would seem they should if anything be energized to put the stem cell clinic sphere in order.

Cue crickets chirping.

The FDA appears at least on the surface not to be doing much of anything on stem cell clinics even as the number of dubious stem cell clinics in the US has stormed past 100. One problem right up the FDAs alley for regulation is that these places are selling and using unapproved products and devices, and in that way putting patients at serious risk. For example, as best as I can tell there has been no recent FDA action on stromal vascular fraction (SVF), a product that the FDA has, at least in the past, defined in no uncertain terms as a biological drug. Meanwhile more and moreclinics sell SVF treatments and it isspiraling out of control.

What is happening as a result of this lack of action by the FDA is bad for the stem cell field and for biomedical science more generally in addition to putting patients at risk as they literally pay to be participants in unapproved, for-profit human experiments. The reputation of the stem cell field overall is also in jeopardy.

Its a weird situation. On the one hand the FDA holds those with good intentions (e.g. biotech and academic researchers working to do clinical trials) to appropriate, relatively strict standards, but on the other hand turns an apparent blind eye to an entire unregulated industry of stem cell clinics.

Even as the number of dubious clinics rockets upward, in the past year or so the FDA has issued no warning letters in this sphere and as best as I can tell not done much of anything. If the lack of FDA action meant that the stem cell clinic sphere was becoming more responsible and safer then Id be cheering that, but instead I think it reflects some change at the FDA that is not encouraging.

The FDA has a unique opportunity to do something to help remedy this situation and clarify the regulatory sphere related to stem cells this year as it is slated to release new guidance sometime in 2014 on amongst other things SVF and other fat stem cell products. Will they punt? Will they stand firm? At this point, its anybodys guess.

Here are the pertinent sections to focus on in the page linked to above:

The FDA tells me they are taking actual actions too in this arena, but they cannot discuss it and the action is not apparent in the public sphereyet.

However, effectively their inaction or slow motion action has created what I have termed default deregulation and this will only become more entrenched as the number of dubious clinics and untrained physicians pitching stem cell interventions without regulatory approval continues to skyrocket.

I often talk to the clinics and as appropriate I sometimes tell them they are not following FDA regulations, etc.

Im not sure if I can even say that anymore since the FDA seems to be in effective hibernation on stem cell clinics.

Are the clinic operators right they can pretty much do whatever they want with whatever devices and products they feel like without worrying about the FDA? Im not sure anymore because it feels like the FDA is all talk and no action lately on stem cell clinics. Well, actually, no talk and no action.

. Bookmark the

.

Read the rest here:
Has the FDA given up on regulating stem cell clinics ...

Stem Cell Treatment May Help Ease Osteoarthritis Pain …

By Uncategorized

Last year, Patricia Beals was told she'd need a double knee replacement to repair her severely arthritic knees or she'd probably spend the rest of her life in a wheelchair.

Hoping to avoid surgery, Beals, 72, opted instead for an experimental treatment that involved harvesting bone marrow stem cells from her hip, concentrating the cells in a centrifuge and injecting them back into her damaged joints.

"Almost from the moment I got up from the table, I was able to throw away my cane," Beals says. "Now I'm biking and hiking like a 30-year-old."

A handful of doctors around the country are administering treatments like the one Beals received to stop or even reverse the ravages of osteoarthritis. Stem cells are the only cells in the body able to morph into other types of specialized cells. When the patient's own stem cells are injected into a damaged joint, they appear to transform into chondrocytes, the cells that go on to produce fresh cartilage. They also seem to amplify the body's own natural repair efforts by accelerating healing, reducing inflammation, and preventing scarring and loss of function.

Christopher J. Centeno, M.D., the rehab medicine specialist who performed Beals' procedure, says the results he sees from stem cell therapy are remarkable. Of the more-than-200 patients his Bloomfield, Colo., clinic treated over a two-year period, he says, "two thirds of them reported greater than 50 percent relief and about 40 percent reported more than 75 percent relief one to two years afterward."

According to Centeno, knees respond better to the treatment than hips. Only eight percent of his knee patients opted for a total knee replacement two years after receiving a stem cell injection. The complete results from his clinical observations will be published in a major orthopedic journal later this year.

The Pros and Cons

The biggest advantage stem cell injections seem to offer over more invasive arthritis remedies is a quicker, easier recovery. The procedure is done on an outpatient basis and the majority of patients are up and moving within 24 hours. Most wear a brace for several weeks but still can get around. Many are even able to do some gentle stationary cycling by the end of the first week.

There are also fewer complications. A friend who had knee replacement surgery the same day Beals had her treatment developed life-threatening blood clots and couldn't walk for weeks afterwards. Six months out, she still hasn't made a full recovery.

Most surgeries don't go so awry, but still: Beals just returned from a week-long cycling trip where she covered 20 to 40 miles per day without so much as a tweak of pain.

As for risks, Centeno maintains they are virtually nonexistent.

"Because the stem cells come from your own body, there's little chance of infection or rejection," he says.

Not all medical experts are quite so enthusiastic, however. Dr. Tom Einhorn, chairman of the department of orthopedic surgery at Boston University, conducts research with stem cells but does not use them to treat arthritic patients. He thinks the idea is interesting but the science is not there yet.

"We need to have animal studies and analyze what's really happening under the microscope. Then, and only then, can you start doing this with patients," he says.

The few studies completed to date have examined how stem cells heal traumatic injuries rather than degenerative conditions such as arthritis. Results have been promising but, as Einhorn points out, the required repair mechanisms in each circumstance are very different.

Another downside is cost: The injections aren't approved by the FDA, which means they aren't covered by insurance. At $4,000 a pop -- all out of pocket -- they certainly aren't cheap, and many patients require more than one shot.

Ironically, one thing driving up the price is FDA involvement. Two years ago, the agency stepped in and stopped physicians from intensifying stem cells in the lab for several days before putting them back into the patient. This means all procedures must be done on the same day, no stem cells may be preserved and many of the more expensive aspects of the treatment must be repeated each time.

Centeno says same day treatments often aren't as effective, either.

But despite the sky-high price tag and lack of evidence, patients like Beals believe the treatment is nothing short of a miracle. She advises anyone who is a candidate for joint replacement to consider stem cells first.

"Open your mind up and step into it," she says. "Do it. It's so effective. It's the future and it works."

Read more from the original source:
Stem Cell Treatment May Help Ease Osteoarthritis Pain ...

Pluripotent Stem Cells 101 | Boston Children’s Hospital

By Induced Pluripotent Stem Cells

Pluripotent stem cells are master cells. Theyre able to make cells from all three basic body layers, so they can potentially produce any cell or tissue the body needs to repair itself. This master property is called pluripotency. Like all stem cells, pluripotent stem cells are also able to self-renew, meaning they can perpetually create more copies of themselves.

There are several types of pluripotent stem cells, including embryonic stem cells. At Childrens Hospital Boston, we use the broader term because pluripotent stem cells can come from different sources, and each method creates a cell with slightly different properties.

But all of them are able to differentiate, or mature, into the three primary groups of cells that form a human being:

Right now, its not clear which type or types of pluripotent stem cells will ultimately be used to create cells for treatment, but all of them are valuable for research purposes, and each type has unique lessons to teach scientists. Scientists are just beginning to understand the subtle differences between the different kinds of pluripotent stem cells, and studying all of them offers the greatest chance of success in using them to help patients.

Types of pluripotent stem cells:

All four types of pluripotent stem cells are being actively studied at Childrens.

Induced pluripotent cells (iPS cells): Scientists have discovered ways to take an ordinary cell, such as a skin cell, and reprogram it by introducing several genes that convert it into a pluripotent cell. These genetically reprogrammed cells are known as induced pluripotent cells, or iPS cells. The Stem Cell Program at Childrens Hospital Boston was one of the first three labs to do this in human cells, an accomplishment cited as the Breakthrough of the Year in 2008 by the journal Science.

iPS cells offer great therapeutic potential. Because they come from a patients own cells, they are genetically matched to that patient, so they can eliminate tissue matching and tissue rejection problems that currently hinder successful cell and tissue transplantation. iPS cells are also a valuable research tool for understanding how different diseases develop.

Because iPS cells are derived from skin or other body cells, some people feel that genetic reprogramming is more ethical than deriving embryonic stem cells from embryos or eggs. However, this process must be carefully controlled and tested for safety before its used to create treatments. In animal studies, some of the genes and the viruses used to introduce them have been observed to cause cancer. More research is also needed to make the process of creating iPS cells more efficient.

iPS cells are of great interest at Childrens, and the lab of George Q. Daley, MD, PhD, Director of Stem Cell Transplantation Program, reported creating 10 disease-specific iPS lines, the start of a growing repository of iPS cell lines.

Embryonic stem cells: Scientists use embryonic stem cell as a general term for pluripotent stem cells that are made using embryos or eggs, rather than for cells genetically reprogrammed from the body. There are several types of embryonic stem cells:

1. True embryonic stem cell (ES cells) These are perhaps the best-known type of pluripotent stem cell, made from unused embryos that are donated by couples who have undergone in vitro fertilization (IVF). The IVF process, in which the egg and sperm are brought together in a lab dish, frequently generates more embryos than a couple needs to achieve a pregnancy.

These unused embryos are sometimes frozen for future use, sometimes made available to other couples undergoing fertility treatment, and sometimes simply discarded, but some couples choose to donate them to science. For details on how theyre turned into stem cells, visit our page How do we get pluripotent stem cells?

Pluripotent stem cells made from embryos are generic and arent genetically matched to a particular patient, so are unlikely to be used to create cells for treatment. Instead, they are used to advance our knowledge of how stem cells behave and differentiate.

2. Stem cells made by somatic cell nuclear transfer (ntES cells) The term somatic cell nuclear transfer (SCNT) means, literally, transferring the nucleus (which contains all of a cells genetic instructions) from a somatic cellany cell of the bodyto another cell, in this case an egg cell. This type of pluripotent stem cell, sometimes called an ntES cell, has only been made successfully in lower animals. To make ntES cells in human patients, an egg donor would be needed, as well as a cell from the patient (typically a skin cell).

The process of transferring a different nucleus into the egg reprograms it to a pluripotent state, reactivating the full set of genes for making all the tissues of the body. The egg is then allowed to develop in the lab for several days, and pluripotent stem cells are derived from it. (Read more in How do we get pluripotent stem cells?)

Like iPS cells, ntES cells match the patient genetically. If created successfully in humans, and if proven safe, ntES cells could completely eliminate tissue matching and tissue rejection problems. For this reason, they are actively being researched at Childrens.

3. Stem cells from unfertilized eggs (parthenogenetic embryonic stem cells) Through chemical treatments, unfertilized eggs can be tricked into developing into embryos without being fertilized by sperm, a process called parthenogenesis. The embryos are allowed to develop in the lab for several days, and then pluripotent stem cells can be derived from them (for more, see How do we get pluripotent stem cells?)

If this technique is proven safe, a woman might be able to donate her own eggs to create pluripotent stem cells matching her genetically that in turn could be used to make cells that wouldnt be rejected by her immune system.

Through careful genetic typing, it might also be possible to use pES cells to create treatments for patients beyond the egg donor herself, by creating master banks of cells matched to different tissue types. In 2006, working with mice, Childrens researchers were the first to demonstrate the potential feasibility of this approach. (For details, see Turning pluripotent stem cells into treatment).

Because pES cells can be made more easily and more efficiently than ntES cells, they could potentially be ready for clinical use sooner. However, more needs to be known about their safety. Concerns have been raised that tissues derived from them might not function normally.

Read more about pluripotent stem cells by following these links:

Read the original here:
Pluripotent Stem Cells 101 | Boston Children's Hospital

PRP Therapy (Platelet-Rich Plasma) – JointRehab.com

By Platelet Rich Plasma Injections

Although PRP (Platelet-Rich Plasma) Therapy has been around since the mid-1990s many people are still unaware of this beneficial treatment.

Various fields of medicine, including dentistry, neurosurgery, wound healing, and orthopedics, have only just begun to scrape the surface of the long-term and ongoing benefits that can result from employing this valuable therapy.

What is it? A Quick Lesson on Blood In a nutshell, a PRP injection delivers a high concentration of endogenous (your own home-grown) platelets to an area of injury.

To understand the therapeutic value of PRP injections, you need to have a basic understanding of the make-up of blood. Blood is composed of plasma, red blood cells, white blood cells, and platelets. Its these platelets that are the injurys first-responders and help revascularize an injured area, construct new tissue, and stop the bleeding.

Because platelets play a significant role in the healing of tissue, reintroducing a high concentration of platelets directly into the injured area may enhance the healing process.

The physiological effects include:

Increase tissue regeneration (tendon, ligament, soft tissue) Decrease inflammation Decrease pain Increase collagen (base component of connective tissue) Increase bone density Increase angiogenesis (development of new blood cells)

In the world of high-stakes sports, many stars swear by it. Tiger Woods received PRP injections in his left knee following surgery, and L.A. Dodgers pitcher, Takashi Saito was able to return to the mound for the 2008 playoffs as a result of this little-known therapy.

Studies have seconded these testimonials. A recent study published in the American Journal of Sports Medicine (2006) reviewed the effectiveness of PRP therapy in patients with chronic elbow pain. Fifteen patients were treated with PRP therapy. The results documented a 60% improvement at eight weeks, 81% at six months, and 93% at final follow-up (12-38 months). There were no side effects or complications reported.

The Trouble with Tendons Tendon injuries often become chronic because of the poor blood supply to these areas. Athletes and active people tend to have these issues and sometimes a whole career or hobby can be ruined by this ongoing complication. A PRP injection allows a quick and focused action to the area of injury, which allows it to heal more effectively and rapidly.

The Procedure A patients blood is drawn and placed in a centrifuge which separates the platelet-rich plasma from the rest of the blood. This plasma is then injected into the area of injury. Its a quick procedure with little, if any, downtime. Its also safe because the platelets are derived from the patients own blood, so there is no risk of rejection or reaction.

Not every patient is treated with PRP. We do not treat every patient with PRP, most often, Dextrose Prolotherapy is used instead of PRP, because of the extra step in drawing your blood, the extra expense in purchasing the PRP kit, and extra time it takes to prepare the platelets. The injections are exactly the same way, but the proliferant, or solution injected is different. For many years we have had great success in healing 1000s of patients and having them avoid surgery with dextrose Prolotherapy.

Your decision to have PRP should be discussed with us to determine which type of Prolotherapy, (Dextrose, platelets, or another proliferant) is best for you.

Not every doctor is proficient in PRP Therapy Platelet Rich Plasma Therapy has become very popular. Physicians who do not do traditional Prolotherapy are now offering PRP. Unfortunately, these untrained doctors are injecting the platelets in a way that is often painful, debilitating for weeks, and can leave hematomas (collections of clotted blood) in the area injected. We believe that PRP is best delivered by a physician already experienced and well versed in Prolotherapy.

Platelet alpha granules contain potent growth factors necessary to begin tissue repair and regeneration at the wound site. Concentrated autologous platelets contain large reservoirs of growth factors that have the potential to greatly accelerate the normal healing process, naturally. The use of concentrated growth factors is considered by many to be a new frontier of clinical therapy

Excerpts in this article from Harvest Technologies Corp

1. Marx, R.E. , et al,Platelet-Rich Plasma Growth Factor Enhancement for Bone Grafts, Oral Surg Oral Med Oral Patrhol, 1998;85:638-646.

2. Antonaides, H.N., et al,Human Platelet-Derived Growth Factor: Structure and Functions, Federation Proceedings, 1983;42:2630-2634.

3. Pierce, G.F., et al,PDGF-BB,TGF-1 and Basic FGF in Dermal Wound Healing: Neovessel and Matrix Formation and Cessation Repair, Am J Pathology, 1992;140:1375-1388.

Marc Darrow, M.D., J.D., utilizes Stem Cell Therapy, Platatelt Rich Plasma Therapy, and Prolotherapy for the treatment of chronoc joint and back pain. Dr. Marc Darrow is a Board Certified Physiatrist specializing in Physical Medicine and Rehabilitation.

Originally posted here:
PRP Therapy (Platelet-Rich Plasma) - JointRehab.com

Stem Cells News — ScienceDaily

By Stem Cell Medicine

Sep. 3, 2015 A number of illnesses causing blindness can be cured from transplanting cells from the oral cavity. New findings make the treatment accessible to the places where the condition strikes the most ... read more Aug. 26, 2015 Compounds found in purple potatoes may help kill colon cancer stem cells and limit the spread of the cancer, according to a team of ... read more Aug. 20, 2015 Scientists have developed a novel way to engineer the growth and expansion of energy-burning 'good' fat, and then found that this fat helped reduce weight gain and lower blood glucose ... read more How Newts Can Help Osteoarthritis Patients Aug. 20, 2015 Osteoarthritis is the most common form of joint disease worldwide. Now, scientists have taken a leaf out of natures book in an attempt to develop effective stem cell treatment for osteoarthritis, ... read more Regenerating Nerve Tissue in Spinal Cord Injuries Aug. 13, 2015 Researchers are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. The therapy uses a population of cells derived from human embryonic ... read more Newly Discovered Cells Regenerate Liver Tissue Without Forming Tumors Aug. 13, 2015 The mechanisms that allow the liver to repair and regenerate itself have long been a matter of debate. Now researchers have discovered a population of liver cells that are better at regenerating ... read more Aug. 12, 2015 Scientists have discovered metabolic rejuvenation factors in eggs. This critical finding furthers our understanding of how cellular metabolism changes during aging, and during rejuvenation after egg ... read more Can Stem Cells Cause and Cure Cancer? Aug. 12, 2015 Simply put, cancer is caused by mutations to genes within a cell that lead to abnormal cell growth. Finding out what causes that genetic mutation has been the holy grail of medical science for ... read more Why Statins Should Be Viewed as a Double-Edged Sword Aug. 12, 2015 Statins have significant cardiovascular benefits, but also serious side effects. A new study finds that statin use impairs stem cell function, which helps in slowing atherosclerosis but hinders other ... read more Researcher Studying Advances in Next-Generation Stem Cell Culture Technologies Aug. 10, 2015 A researcher is studying ways to advance the next generation of cell culture technologiesthe removal of stem cells from an organism and the controlled growth of those cells in an engineering ... read more Stem Cells Help Researchers Study the Effects of Pollution on Human Health Aug. 10, 2015 Embryonic stem cells could serve as a model to evaluate the physiological effects of environmental pollutants efficiently and cost-effectively. The use of stem cells has found another facade. In the ... read more Aug. 5, 2015 Scientists have, for the first time, found further evidence of how the differentiation of pluripotent cells is tied to and controlled by the cell cycle clock. This deeper understanding of how cells ... read more From Pluripotency to Totipotency Aug. 4, 2015 While it is already possible to obtain in vitro pluripotent cells (i.e., cells capable of generating all tissues of an embryo) from any cell type, researchers have pushed the limits of science even ... read more Precision Medicine Brought One Step Closer to the Clinic Aug. 3, 2015 A revolutionary, high-throughput, robotic platform has been designed that automates and standardizes the process of transforming patient samples into stem cells. This unique platform for the first ... read more Aug. 3, 2015 Investigators report that they have been able to drive cells to grow into muscle fibers, producing millimeter-long muscle fibers capable of contracting in a dish and multiplying in large numbers. ... read more July 30, 2015 Evaluating drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Now, scientists report that they produced large amounts of ... read more How a Single Molecule Turns One Immune Cell Into Another July 30, 2015 All it takes is one molecule to reprogram an antibody-producing B cell into a scavenging macrophage. This transformation is possible, new evidence shows, because the molecule (C/EBPa, a transcription ... read more July 29, 2015 A first-of-its kind prostate 'organoid' grown from human embryonic stem cells has enabled researchers to show that exposure to bisphenol A, a chemical in many plastics, can cause ... read more Scientists Identify Gene Vital for Rebuilding Intestine After Cancer Treatment July 29, 2015 A rare type of stem cell is immune to radiation damage thanks to high levels of a gene called Sox9, researchers have ... read more New Drug for Blood Cancers Now in Five Phase II Clinical Trials July 28, 2015 The safety and dosing of a new drug for treating blood cancers has now been established by a group of scientists. The drug is a small molecule inhibitor that suppresses the activity of a signaling ... read more

Go here to read the rest:
Stem Cells News -- ScienceDaily

Doctors Question Perry’s Stem Cell Back Treatment

By Stem Cell Doctors

Associated PressAugust 19, 2011

He calls it innovative. Others call it a big risk. In any case, the stem cell procedure that Texas Gov. Rick Perry had last month was an unusual experiment to fix a common malady: a bad back. Perry and his doctor chose a treatment beyond mainstream medicine: He had stem cells taken from fat in his own body, grown in a lab and then injected into his back and his bloodstream during a July 1 operation to fuse part of his spine.

Some top scientists are questioning the safety and wisdom of Perry's treatment, especially because it was not part of a clinical trial in which unproven therapies are tested in a way that helps protect patients and advances medical knowledge.

It used Perry's own "adult" stem cells.Adult stem cells have long been used to treat cancers such as leukemia and lymphomait's what doctors are using when they do bone marrow transplants.

Perry, however, had an even more experimental procedure: stem cells from fat removed by liposuction and grown in a lab for some time before they were put into his spine and bloodstream.

Besides safety concerns, little is known about whether such cell therapies work.

Patients may believe cells helped them, but there's no way to know they did unless a study is done comparing those who did and did not receive such treatment, said Dr. Scott Rodeo, an orthopedic surgeon at Hospital for Special Surgery in New York. He was a physician to the USA Olympics Teams in 2004 and 2008 and is associate team physician for the New York Giants football team.

Read the full story at news.yahoo.com.

More:
Doctors Question Perry's Stem Cell Back Treatment

Embryonic stem cell research: an ethical dilemma | Europe …

By Embryonic Stem Cells

A human embryo can split into twins or triplets until about 14 days after fertilization

Egg and sperm: some people believe an embryo must be fully protected from conception onwards (Wellcome Images/Spike Walker)

Human blastocyst on the tip of a pin: embryonic stem cells can be grown from cells found in the blastocyst (Wellcome Images/Yorgos Nikas)

Some people think an embryo deserves special protection from about 14 days after fertilization

Many patients could one day benefit from embryonic stem cell research

The rules controlling embryonic stem cell research vary around the world and have been the topic of much discussion

Embryonic stem cell research poses a moral dilemma. It forces us to choose between two moral principles:

In the case of embryonic stem cell research, it is impossible to respect both moral principles.To obtain embryonic stem cells, the early embryo has to be destroyed. This means destroying a potential human life. But embryonic stem cell research could lead to the discovery of new medical treatments that would alleviate the suffering of many people. So which moral principle should have the upper hand in this situation? The answer hinges on how we view the embryo. Does it have the status of a person?

Chapter 1 of this film introduces some of the key ethical arguments. Watch this film and others on our films page.

The moral status of the embryo is a controversial and complex issue. The main viewpoints are outlined below.

1. The embryo has full moral status from fertilization onwards Either the embryo is viewed as a person whilst it is still an embryo, or it is seen as a potential person. The criteria for personhood are notoriously unclear; different people define what makes a person in different ways.

Development from a fertilized egg into to baby is a continuous process and any attempt to pinpoint when personhood begins is arbitrary. A human embryo is a human being in the embryonic stage, just as an infant is a human being in the infant stage. Although an embryo does not currently have the characteristics of a person, it will become a person and should be given the respect and dignity of a person.

An early embryo that has not yet implanted into the uterus does not have the psychological, emotional or physical properties that we associate with being a person. It therefore does not have any interests to be protected and we can use it for the benefit of patients (who ARE persons).

The embryo cannot develop into a child without being transferred to a womans uterus. It needs external help to develop. Even then, the probability that embryos used for in vitro fertilization will develop into full-term successful births is low. Something that could potentially become a person should not be treated as if it actually were a person

2. There is a cut-off point at 14 days after fertilization Some people argue that a human embryo deserves special protection from around day 14 after fertilization because:

3. The embryo has increasing status as it develops An embryo deserves some protection from the moment the sperm fertilizes the egg, and its moral status increases as it becomes more human-like.

There are several stages of development that could be given increasing moral status:

1. Implantation of the embryo into the uterus wall around six days after fertilization. 2. Appearance of the primitive streak the beginnings of the nervous system at around 14 days. 3. The phase when the baby could survive if born prematurely. 4. Birth.

If a life is lost, we tend to feel differently about it depending on the stage of the lost life. A fertilized egg before implantation in the uterus could be granted a lesser degree of respect than a human fetus or a born baby.

More than half of all fertilized eggs are lost due to natural causes. If the natural process involves such loss, then using some embryos in stem cell research should not worry us either.

We protect a persons life and interests not because they are valuable from the point of view of the universe, but because they are important to the person concerned. Whatever moral status the human embryo has for us, the life that it lives has a value to the embryo itself.

If we judge the moral status of the embryo from its age, then we are making arbitrary decisions about who is human. For example, even if we say formation of the nervous system marks the start of personhood, we still would not say a patient who has lost nerve cells in a stroke has become less human.

If we are not sure whether a fertilized egg should be considered a human being, then we should not destroy it. A hunter does not shoot if he is not sure whether his target is a deer or a man.

4. The embryo has no moral status at all An embryo is organic material with a status no different from other body parts.

Fertilized human eggs are just parts of other peoples bodies until they have developed enough to survive independently. The only respect due to blastocysts is the respect that should be shown to other peoples property. If we destroy a blastocyst before implantation into the uterus we do not harm it because it has no beliefs, desires, expectations, aims or purposes to be harmed.

By taking embryonic stem cells out of an early embryo, we prevent the embryo from developing in its normal way. This means it is prevented from becoming what it was programmed to become a human being.

Different religions view the status of the early human embryo in different ways. For example, the Roman Catholic, Orthodox and conservative Protestant Churches believe the embryo has the status of a human from conception and no embryo research should be permitted. Judaism and Islam emphasize the importance of helping others and argue that the embryo does not have full human status before 40 days, so both these religions permit some research on embryos. Other religions take other positions. You can read more about this by downloading the extended version of this factsheet below.

Extended factsheet with a fuller discussion of the issues by Kristina Hug (pdf) EuroStemCell film "Conversations: ethics, science, stem cells" EuroStemCell factsheet on ethical issues relating to the sources of embyronic stem cells EuroStemCell factsheet on the science of embryonic stem cells EuroStemCell FAQ on human embryonic stem cells and their use in research EuroStemCell summaries of regulations on stem cell research in Europe Booklet for 16+ year olds about stem cells and ethics from the BBSRC Research paper on the ethics of embryonic stem cell research by Kristina Hug

This factsheet was created by Kristina Hug and reviewed by Gran Hermern.

Images courtesy of Wellcome Images: Egg and sperm by Spike Walker; Blastocyst on pin by Yorgos Nikas; Diabetes patient injecting insulin by the Wellcome library, London.

Other images from "Conversations : ethics, science, stem cells", a film by EuroStemCell.

Visit link:
Embryonic stem cell research: an ethical dilemma | Europe ...

STAP cells | Knoepfler Lab Stem Cell Blog

By Stell Cell Research

Post navigation

For the past few years post-publication peer review (PPPR) has grown in influence and one particular website, PubPeer, has become the primary go-to place specifically for bluntPPPR. The kind that happens in journal clubs in labs across the world. Comments on PubPeer have led to numerous serious corrections and retractions of flawed articles. Im most familiar with its role in the STAP cell case.

Both the founders of and most of the commenters on PubPeer have remained anonymous.

That is until today.

The founders of PubPeer have publicly identified themselves in a blog post and formed a new non-profit organization, The PubPeer Foundation.

PubPeer founders include Brandon Stell, George Smith and Richard Smith. Also with the founders on the PubPeer Foundation Board of Directors will be Boris Barbour and Gabor Brasnjo.

Who are these guys?

RetractionWatch (big HT to them) has an interesting interview with PubPeer founder Stell. I highly recommend reading it. Jennifer Couzin-Frankel over at Science also has a nice piece on this development.

Stell is a neuroscientist and Co-Team Leader at the Brain Physiology Lab in Paris, the source of his picture above.

I was trying to learn more about the other two founders, George Smith and Richard Smith. From Couzin-Frankels piece it appears that the brothers want to remain relatively out of the limelight, and their very common names may very well aid them in that. Couzin-Frankel does write that Richard was a grad student who briefly worked in Stells lab and George is a web developer.

As to the Foundation, RetractionWatch has a helpful quote from Stell on looking ahead:

What role do you hope PubPeer plays moving forward? What plans do you have for the Foundation?

We hope that the PubPeer Foundation will provide us with more opportunities to develop the site in ways that will help grow the community of post-publication peer reviewers and further encourage quality science.As more of us scientists become accustomed to commenting on papers, and as that becomes more of a part of the overall scientific process, I think well be able to finally up-end the backwards reward structure that is currently in place in science. Hopefully we can get to a point where the data are much more important to a scientists career than the journal that published them.

To form the PubPeer Foundation, the leaders could not remain anonymous. It seems like a good thing that the founders of PubPeer have identified themselves. They deserve a lot of credit for having had a transformative impact on how science corrects itself. Theyve also faced tough situations such as being sued by Fazlul Sarkar, a case that is still working its way through the legal system. Sarkar wants to know the identity of some anonymous PubPeer commenters. I predict that the PubPeer Foundation will now receive substantial financial support, which in part can be used to get legal assistancefor possible future challenges.

PubPeer has grown quickly, now has a striking following with around 300,000 pageviews/month and contains 35,000 total comments.

Obokata late press conference

The Japanese public broadcasting system, NHK, has been accused by scientist Haruko Obokata of violating her human rights.

Obokata was the primary researcher involved in the STAP cell fiasco in which two ultimately retracted Nature papers contained duplicated, plagiarized, and manipulated data. She was certainly not the only researcher on those papers, but overall she has been accused of having the most central role in the STAP problems. Obokata left RIKEN late in 2014.

During the height of the STAP cell mess the Japanese media hounded Obokata and other STAP cell authors including Yoshiki Sasai, who ultimately committed suicide. From accounts in Japan, the STAP cell story was on the equivalent of the nightly news and on the front of national newspapers and tabloids almost every day for a time.

For instance, NHK was incredibly persistent with pursing Obokata and now Obokata has said that they violated her human rights in a complaint to the Japanese Broadcasting Ethics & Program Improvement Organization or BPO. Obokata asserts that NHK violated her rights in numerous ways including accusing her of stealing embryonic stem cells and she sustained injuries while being pursued by NHK. BPO will be investigating these and other assertions by Obokata against NHK.

During the STAP cell mess last year, it seems because I was covering the STAP cell claims and science here on this blog, many members of the Japanese media emailed and called me. I can understand that they were looking for information and perspectives, but it went out of control in certain cases. Some, including reporters saying they were from NHK, were very aggressive with me. They some persistently called me at work and even at home in the middle of the night.

I had decided to not talk with them because of their aggressiveness and their tendency to focus on negative, personal stories rather than the science and facts, but they wouldnt take no for an answer. Several pursued me for comment at conferences too. I dont have direct knowledge of what happened with Obokata and NHK, but my sense is that the media went way out of bounds on STAP and made it personal.

Who can forget the STAP cell scandal of last year?

Now almost a year and a half after the deeply flawed papers first were published, where do things stand?

As an international collaboration there were both American and Japanese sides to STAP.

In the US, STAP still remains eerily quiet.

In a month or so, the one-year sabbatical of STAP cell paper senior author, Professor Charles Vacanti of Brigham and Womens Hospital and Harvard Medical School, is scheduled to end.

There has been no public disclosure as to whether (or if) there was or is an institutional investigation into the possible roles of Vacanti and his trainee Koji Kojima in the fiasco that ultimately led to the retraction of two Nature papers.

In contrast, in Japan there have already been many serious repercussions for the STAP cell authors including Haruko Obokata, who was forced out of RIKEN after she couldnt reproduce STAP. See a full STAP cell timeline here.

Just recentlyit was announced that Obokata has been forced to repay the publication fees for the Nature papers. Not a big deal in it of itself, but still just another repercussion for her. The same article quoted an Obokata attorney that her physical condition is a concern.

Vacanti and Obokata

Overallthere has been and continues to be this tension between the reaction to STAP in the US and in Japan.

Well beyond Obokata, many other researchers in Japan have been negatively affected by the fallout from STAP. I dont think its an exaggeration to call it a scientific disaster. In the US, there has been pretty much no apparent fallout. Who knows, it may stay that way.

In the mean time the retracted STAP papers have become in a relatively short period extremely highly cited publications (e.g. 160 citations for one on GoogleScholar). A brief look makes clear that notall those citations are referring tothe papers as an example of what can go wrong either. Some are referring to the supposed science as if it was real, which is pretty sad.

We also never really did hear any meaningful discussion of STAP from Nature either. They pretty much sidestepped any responsibility. Hopefully they have brought online a more rigorous manuscript evaluation system like the one used by EMBO.

Brigham and Womens and Harvard face another stem cell hot potato in the controversy related to the work of cardiac stem cell researcher Piero Anversa. In that case the institution(s) did investigate and Anversa has sued them over how the investigation was handled. To my knowledge that situation remainsunresolved.

Could this other situation be a factor in how those two linked institutions viewSTAP? Again, for all we know there never was an investigation of Vacantis or Kojimas potential roles in STAP.

As more time passes, I dont think necessarily it means that the STAP issue will go away on this side of the world. Without more information on how the STAP storyevolvedhere in the US, it seems to me that the STAP issue overall cannot have full clarity and the lessons from it are incomplete. More facts and transparency on how that project developedare needed still. Will that ever happen? I dont know.

Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly some of them may have been more hopes than predictions.

At mid-year today on June 30th, how am I doing? See below. Note that of course for some the jury is still out.

BTW, stay tuned for more on an upcoming update on the Japan IPSC macular degeneration trial where there seems to have been a (hopefully minor) hitch.

The annual ISSCR meeting has started in Stockholm.

This is always a great annual meeting both for the science and for connecting with people including new friends and colleagues as well as old friends.

Another element to the meeting is the insider conversations in the halls, restaurants, and bars that tell a behind the scenes story of the stem cell field.

Beloware my top 10 things to look for that might be discussed over a beer or coffee this year.Also be sure to check out the wonderfulguide to Stockholm from Heather Main and if you are there at the meeting enter our stem cell contests to win up to $100.

See original here:
STAP cells | Knoepfler Lab Stem Cell Blog

Platelet Rich Plasma (PRP) Treatment in Hyderabad India

By Platelet Rich Plasma Injections

What isPlatelet Rich Plasma

Eternesse Anti Aging Clinicis the only clinic in India that currently offersPRPto its patients.Platelet Rich Plasma, orPRP, isblood plasma with concentrated plateletsand othergrowth factors. The concentrated platelets found inPRPcontain huge reservoirs ofbioactive proteins, includinggrowth factorsand signaling proteins that are vital to initiate and acceleratetissue repairandregeneration. These growth factors number at least a dozen different factors. Thesebioactive proteinsinitiate connective tissue healing in tissues such asmeniscus (knee)androtator cuff tissue, boneandarticular cartilage regenerationand repair, promote development of new blood vessels, and stimulate thewound healing process.

ThePRPsignals the body to send instem cellsto repair the area of injury.PRP injectionsare sometimes done under fluoroscopic guidance (living x-ray) atEternesse Anti Aging Clinic. This is done for precise localized delivery of these healing factors into injured ligaments, muscles, and joints.

Steps Involved in Platelet Rich Plasma Therapy

Platelet Rich Plasma therapyis a treatment option for variousorthopaedic injuriesand conditions, which have traditionally required surgery or other extensive treatments.PRP injectionsare being utilized inorthopaedicswith increasing frequency and effectiveness. Injuries currently being treated with thePRP therapyare arthritis of the hip, knee, shoulder, ankle and other joints.PRPalso is utilized for soft tissue injuries such astendonitis, muscle sprainsandtears,and various types ofligament injuries. These include common tendon injuries such astennis and golfers elbow,Achilles tendonitisandknee tendonitis. PRP is also used to treat various injuries and conditions affecting (joint) injuries. These include rotator cuff and meniscus injuries.

AlthoughPRPtechnology is consideredcutting edge technology, it was initially developed 20 years ago for heart surgery to aid with the wound healing and blood loss. Its benefits are now being applied towards the facilitating of healing muscle, tendons, ligaments, articular and meniscal injuries. In fact, PRP has been widely used in Europe for many years.

To preparePRP, a small amount of blood is taken from the patients arm. The blood is then placed in acentrifuge. The centrifuge spins and separates the platelets form the rest of the blood components. The entire process takes less than 15 minutes and increases the concentration of platelets and growth factors up to 600%. Using the patients own blood, specially prepared platelets are taken and re-injected into the affected area. These platelets release special growth factors that lead to tissue healing. By using theconcentrated platelets, we increase the growth factors up to eight times which promotes temporary relief and stops inflammation.PRP injectionsactually heal the area over a period of time. This can be anywhere from one to three months.

The human body has a remarkable ability to heal itself, and by re-injecting concentrated platelets, we are facilitating thenatural healing process. ThePRPinjections are calling instem cellsto repair the area. When performing these injections, we must do whatever we can to maximize stem cell release to optimize healing.

PRP is a non-surgical technique which would suggest it is more convenient than a surgery.

Platelets are one of the primary constituents of blood along with white blood cells, red blood cells and plasma.

Platelets in the blood are responsible for the release of growth factors-power proteins which help repair and regenerate soft tissues.

Using a special procedure, we can extract the platelets out of the blood and increase their concentration by 1000 %. When injected into the knee, these highly concentrated platelets aid in the speedy healing of the knee.

We know certain factors diminish stem cell release such as smoking and alcohol intake. Obviously avoiding these pitfalls will do nothing but increase the success of the procedure. The platelets work by causing an inflammatory reaction. If we somehow diminish this inflammatory reaction than we may significantly decrease the chances of having a good result. For this reason, the use of anti-inflammatory drugs such as Advil, Aleve, Motrin, ibuprophen etc. are not recommended. This restriction should be in place for about 4-6 weeks.

The use ofomega 3-fish oiland othernatural anti-inflammatory agentsdo not seem to work the same way as theNSAIDS(non-steroidal anti-inflammatories) and are thus not restricted.

What is the number of injections that are administered?

The number of injections performed depends upon the severity and the type of condition being treated. Age also seems to have an effect on the number of injections given. Typically, younger people generally need fewer injections for the same condition than a person who is older.

Is there any pain involved?

After the injection is given, there is usually a marked increase in pain for anywhere from 5-10 days. Tylenol and possibly a mild narcotic usually handle this pain. The pain may start up again only later to go away. A good analogy is that of a roller coaster where the initial few days are like the big drop on the roller coaster than the remaining few days are like smaller dips on a roller coaster!

We are Indias bestPRP Therapy provider. Dr. Leroy Rebello is Indias foremost expert and authority on Platelet Rich Plasma. If you are anorthopedist making aninquiry for your patient or someone suffering from bone injuries please contact us. If you simply want to rejuvenate your face and body using growth cells, then you are in good hands with the countrys best PRP specialist who will attend upon you. You can call us on the number below for an initial consultation with Dr. Rebello.

Continued here:
Platelet Rich Plasma (PRP) Treatment in Hyderabad India

→←